RxDoctor Payments Data

Alan Bell, MD

Neurology · Hopedale, MANPI 1376643478

Payments from drug & device makers

$27,876in general payments, 2019–2025

Across 1,309 payments — averaging $21.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Lundbeck LLC$2K
  • Novartis$2K
  • Biogen$2K
  • MDD US Operations, LLC$1K
  • SK Life Science, Inc.$932
  • plus $16K from 54 others

What the payments were for

  • Speaking & faculty fees$1,0594%
  • Food & beverage$26,36695%
  • Education$4502%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)169$3,827
Lundbeck LLC93$2,196
Novartis87$1,887
Biogen70$1,556
MDD US Operations, LLC47$1,179
SK Life Science, Inc.41$932
Pfizer62$923
EMD Serono, Inc.31$917
Amneal Pharmaceuticals LLC44$907
UCB, Inc.50$903
Eisai Inc.47$888
Teva Pharmaceuticals USA, Inc.50$825
AstraZeneca(2 entities)34$815
Sanofi27$692
Lilly USA, LLC36$645
Neurocrine Biosciences, Inc.28$639
Merz Pharmaceuticals, LLC21$598
Mallinckrodt Hospital Products Inc.16$594
Sunovion Pharmaceuticals Inc.35$553
CSL Behring22$506
ANI Pharmaceuticals, Inc.22$504
Acorda Therapeutics, Inc24$379
Johnson & Johnson16$337
Supernus Pharmaceuticals, Inc.17$334
Bristol Myers Squibb15$325
Amgen(2 entities)13$309
Biohaven Pharmaceutical Holding Company Ltd.17$259
Mallinckrodt Enterprises LLC11$258
Acadia Pharmaceuticals Inc22$245
Genentech USA, Inc.15$244
Neurelis, Inc.9$196
Grifols USA, LLC11$194
Idorsia Pharmaceuticals US Inc3$173
Otsuka America Pharmaceutical, Inc.7$160
Alnylam Pharmaceuticals Inc.7$152
Impel Pharmaceuticals Inc.8$135
Takeda Pharmaceuticals U.S.A., Inc.6$125
Avanir Pharmaceuticals, Inc.6$117
GE HealthCare7$116
Tanabe Pharma America, Inc.5$113
Arbor Pharmaceuticals, Inc.5$108
Biohaven Pharmaceuticals, Inc.4$102
Harmony Biosciences LLC2$87
Argenx US, Inc.4$83
TG Therapeutics, Inc.4$80
Inspire Medical Systems, Inc.4$78
Avion Pharmaceuticals4$67
Vanda Pharmaceuticals Inc.2$59
Assertio Therapeutics, Inc.3$55
Life Molecular Imaging Ltd3$55
E.r. Squibb & Sons, L.L.C.2$48
Zyla Life Sciences, Inc.3$42
Insightec,inc2$42
Catalyst Pharmaceuticals, Inc.1$35
Xeris Pharmaceuticals, Inc.2$34
Globus Medical1$31
Adamas Pharmaceuticals, Inc.2$31
Axsome Therapeutics, Inc.2$31
Scilex Pharmaceuticals Inc.1$25
Sanofi-aventis U.S. LLC1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$27,876 in reported general payments places this provider in the 75th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$153,043
Medicare patients
390
Services billed
2,648

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5021$295,672
VumerityDiroximel Fumarate11$89,163
Nurtec OdtRimegepant Sulfate35$68,731
BotoxOnabotulinumtoxina27$45,113
NuedextaDextromethorphan Hbr/Quinidine25$36,395
Aimovig AutoinjectorErenumab-Aooe17$24,003
GlatopaGlatiramer Acetate11$17,993
AptiomEslicarbazepine Acetate13$17,350
Carbamazepine ErCarbamazepine69$13,734
OxycontinOxycodone Hcl21$13,634
Lacosamide54$13,148
Carbidopa13$8,807
Ajovy AutoinjectorFremanezumab-Vfrm11$7,696
Memantine Hcl176$6,430
Clobazam12$6,137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
CSL BehringPrivigen$506$295,67221 claims
BiogenVumerity$1,556$89,16311 claims
PfizerNurtec Odt$923$68,73135 claims
AbbVieBotox$3,827$45,11327 claims
Avanir Pharmaceuticals, Inc.Nuedexta$117$36,39525 claims
Sunovion Pharmaceuticals Inc.Aptiom$553$17,35013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 761 neurology providers in Massachusetts.

Other neurology in Hopedale

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →